CS
SPRB

Credit Suisse’s Spruce Biosciences SPRB Stock Holding History

Credit Suisse’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Hold
0
– – – 4357
2022
Q2 		– Hold
0
– – – 4396
2021
Q2 		– Sell
-319
Closed -$397K – 4644
2021
Q1 		$397K Sell
319
-24
-7% -$36.8K ﹤0.01% 3900
2020
Q4 		$625K Buy
+343
New +$569K ﹤0.01% 3676

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse's SPRB Position: Q3 2022 in Review

Credit Suisse held its Spruce Biosciences (SPRB) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4357.

Credit Suisse first reported a position in SPRB in Q4 2020 and has held it in 2 quarters since. The position peaked at $625K in Q4 2020. 35 funds tracked by Wall St. Rank hold SPRB as of Q3 2022.

  • Credit Suisse held 0 shares of Spruce Biosciences worth $0 as of Q3 2022.
  • Credit Suisse left its Spruce Biosciences share count unchanged in Q3 2022.
  • Spruce Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4357 holding.
  • Credit Suisse first reported a position in Spruce Biosciences in Q4 2020 and has held it in 2 quarters since.
  • Credit Suisse's Spruce Biosciences position peaked at $625K in Q4 2020.
  • 35 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.